MODULE 10: PHARMACOVIGILANCE
dedicated information on the safety of medicines for neonates, children and adolescents at the time of marketing authorization is therefore very limited, which poses even more reliance on proper pharmacovigilance in the post-marketing stage (9). Fig. 10.1. Timeline of pharmacovigilance for a drug from development (pre-market) to post-marketing use
Download MODULE 10: PHARMACOVIGILANCE
Information
Domain:
Source:
Link to this page:
Documents from same domain
INVESTING IN HEALTH FOR ECONOMIC …
www.who.int2 INVESTING IN HEALTH FOR ECONOMIC DEVELOPMENT Report by the Mexican Commission on Macroeconomics and health 3 The …
WHO GOOD PRACTICES FOR PHARMACEUTICAL …
www.who.intworking document qas/09.297/rev.2 page 2 schedule for the proposed adoption process of document qas/09.297/rev.2: who good practices for pharmaceutical microbiology laboratories
NORMES ET STANDARDS EN INFRASTRUCTURES …
www.who.intnormes et standards en infrastructures et equipements du centre de sante et de promotion sociale, du centre medical avec antenne chirurgicale et du …
Heterotrophic Plate Count Measurement in …
www.who.intWorld Health Organization Sustainable Development and Healthy Environments Heterotrophic Plate Count Measurement in Drinking Water Safety Management
Annex 3 WHO good manufacturing practices for ...
www.who.int96 Introduction The fi rst WHO draft text on good manufacturing practices (GMP) was prepared in 1967 by a group of consultants at the request of the Twentieth
Annex 5 WHO good distribution practices for …
www.who.int236 1. Introduction Distribution is an important activity in the integrated supply-chain management of pharmaceutical products. Various people and entities are
Annex 2 WHO good practices for pharmaceutical …
www.who.int71 Introduction and scope of document Pharmaceutical microbiology laboratories may be involved in: — sterility testing; — detection, isolation, enumeration and identifi cation of microorganisms
LABORATORY BIOSAFETY MANUAL - WHO
www.who.intinterim guidelines WHO/CDS/CSR/LYO/2003.4 LABORATORY BIOSAFETY MANUAL SECOND EDITION (REVISED) WORLD HEALTH ORGANIZATION Geneva 2003
Mycobacteriology Laboratory Manual - WHO
www.who.intMycobacteriology Laboratory Manual ii Edita Pimkina, Infectious Diseases and Tuberculosis Hospital Affi liate of Public institution …
Laboratory Guidelines for enumerating CD4 T …
www.who.intSEA-HLM-392 Distribution: Limited Laboratory Guidelines for enumerating CD4 T Lymphocytes in the context of HIV/AIDS Regional Office for South-East Asia
Related documents
FOR CHILDREN OF MEDICINES - WHO
www.who.intPharmacovigilance and medicine safety issues in children are relevant to everyone who has an interest in and cares about the health of children. The purpose of this guideline is I) to present a case for the importance of the improving safety monitoring of medicines for children, II) to describe possible ways of achieving it
HEALTHCARE IN DENMARK AN OVERVIEW
www.healthcaredenmark.dkChapter 9 describes the rules and regulations that govern medicines and pharmacies, including pharmacovigilance, procurement and pricing of pharmaceutical products as well as reimbursement available to patients. This chapter also briefly touches upon health research, including ethical issues.
E 2 E Pharmacovigilance Planning (Pvp)
www.ema.europa.eueffective pharmacovigilance that can enable information feedback to the users of medicines in a timely manner. Industry and regulators have identified the need for better and earlier planning of pharmacovigilance activities before a product is approved or a license is granted. This ICH
Guideline on good pharmacovigilance practice (GVP)s
www.ema.europa.eusafety data in the paediatric population, including data on possible long -term adverse effects. As mandated by this Regulation, the European Medicines Agency (the ‘Agency’) issued the Guideline on the Conduct of Pharmacovigilance for Medicines Used in the Paediatric Population
Package leaflet: Information for the user Magnaspartate ...
www.medicines.org.ukchildren. Do not use this medicine after the expiry date which is stated on the sachet and carton after EXP. The expiry date refers to the last day of that month. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment. 6.
AUSTRALIAN PRODUCT INFORMATION COVID-19 Vaccine ...
www.tga.gov.auThe safety and efficacy of COVID-19 Vaccine AstraZeneca in children and adolescents (aged<18years old) have not yet been established. No data are available. Method of administration COVID-19 Vaccine AstraZeneca is for intramuscular (IM) injection only, preferably in the deltoid muscle.
Public Assessment Report
assets.publishing.service.gov.ukAdequate evidence of safety and efficacy to enable the MHRA to conclude that the benefits are greater than the risks is required. Any new information on COVID-19 Vaccine AstraZeneca will be reviewed every year and this report will be updated as necessary. In line with the legal requirements for children's medicines, the application included a